Expert Opin Investig Drugs 32(5):355359 Urva S, Coskun T, Loh MT, Du Y, Thomas MK, Gurbuz S et al (2022) LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial
Our experience shows it offers a great balance between ease of measurement and vial longevity
This makes it an absolutely vital compound for comparative studies examining how different incretin receptor combinations directly influence liver fat reduction, cardiovascular metabolic health, and overarching energy utilization under controlled experimental stressors
GLP1/2 fusion Fc proteins have been shown to lower weight, alleviate fibrosis, improve tight junctions, and increase microvillus height (Kim et al., 2022)
2025 Sep 17;393(11):107787
L.MaT.ClemmensenC.et al